• Publications
  • Influence
Juvenile polyarteritis: results of a multicenter survey of 110 children.
There were remarkable differences among pediatric patients with PAN, with different clinical manifestations and overall better survival and lower relapse rates when compared with adults. Expand
Long‐term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients
To investigate the long‐term outcome and prognostic factors of juvenile dermatomyositis (DM) through a multinational, multicenter study.
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial
The safety and efficacy of abatacept, a selective T-cell costimulation modulator, in children with juvenile idiopathic arthritis who had failed previous treatments was assessed. Expand
Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis.
The hypothesis that ANA-positive patients classified into different JIA categories by current ILAR criteria constitute a homogeneous patient population is substantiated. Expand
EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology
EULAR/PRINTO/PRES propose validated classification criteria for HSP, c-PAN,c-WG and c-TA, with substantial/almost perfect agreement with the final consensus classification or original treating physician diagnosis. Expand
Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial
Combined treatment with prednisone and either ciclosporin or methotrexate was more effective thanprednisone alone, and the safety profile and steroid-sparing effect favoured the combination of prednis one plus metotrexate. Expand
Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial.
In patients with JIA in remission, a 12-month vs 6-month withdrawal of methotrexate did not reduce the relapse rate and low MRP8/14 levels indicated a low risk of flares within the next 3 months following the biomarker test. Expand
Abatacept improves health‐related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis
To assess health‐related quality of life (HRQOL) in abatacept‐treated children/adolescents with juvenile idiopathic arthritis (JIA), a large number of children and adolescents with JIA are treated with statins. Expand
Discrimination between incomplete and atypical Kawasaki syndrome versus other febrile diseases in childhood: results from an international registry-based study.
This is the largest series of incomplete and atypical KS patients of non East-Asian ancestry and it is suggested that in patients with the aforementioned clinical features and laboratory evidence of systemic inflammation in terms of increased C-reactive protein and platelet counts an echocardiogram should be performed and diagnosis of KS considered. Expand
Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort study.
It was found that patients with JIA have a significant impairment of their HRQOL compared with healthy peers, particularly in the physical domain, and physical well-being was mostly affected by the level of functional impairment, whereas the intensity of pain had the greatest influence on psychosocial health. Expand